Member Info for a-2-b

I wonder if they took this into consideration before the trial: https://twitter.com/UMAS_SONESPASES/status/1005198285659955200

I looked through that and it did call the trial was a success. If you look through the European trials page it says it's still on-going as I'm guessing its joining on the extension. On that pdf though she references as a potential treatment for Sj�gren's syndrome and Crohn's disease. This really has me convinced that people were misdiagnosed before they entered the trial: https://www.uofmhealth.org/health-library/hw117739 https://resources.lupus.org/entry/how-lupus-affects-the-gastrointestinal-system (Look @ Ulcerative colitis and crohn�s disease)

thats amazing just seen so glad its helped them

Actually it's there now

Definitely something happening here directors can't buy shares due to the inside info they know, and we haven't had the annual report and agm notice which we were promised on the same day.

As what is means, bigger companies are running/beginning to run trials. Wouldn't be the first time.

You could argue that the US cohort was sabotaged, subjected to error as results are uncharacteristic from the rest. Even on the basis of responders Lupuzor is more effective but not statistically. In the antibody positive cohort it was pretty much the same as the SOC but due to the safety and the bonus of having a fully working immune system still outweighs SOC.

I think FDA approval would easily happen within a year. The safety profile beats anything hands down currently on the market and that's one of the main criteria for approval.

Assuming there were equal numbers in the European cohort that would be 21-22 total patients between 2 groups in Mauritius. Signifying that they all went into remission and are all symptom free!

Very confident with that info now. I've added another 15,000 shares glad to see it's actually helping people gla

A fella from Mauritius has left excellent results on lupuzor. Thanks for making me look into that better lol

In contact with company today I asked them if the directors would be putting their money where there mouth is due to their confidence and they said 'If they are privy to the inside information unable to buy shares under aim rules' which tells me something must be looming.

I doubt it they haven't backed it up with a link this is the best you'll find anyways https://www.patientslikeme.com/treatments/show/28353-sle-phase-iii-lupuzor-side-effects-and-efficacy And a blog calling people to come forward from the trial and give their opinion.

http://www.nimbustx.com/2018/06/05/nimbus-therapeutics-announces-65-million-in-new-financing-to-accelerate-pipeline-progress-and-expand-discovery-efforts/ Not sure if it's relative, seems like a company that would have some interest though.

There's only so much CS a person can have in a lifetime though and it's not a lot as it can cause a lot of problems in itself.

I wonder what will be the topics of the AGM will be. We know placings won't be coming into it anyway. Probably just re-appointments.

Happy to wait about here have a few atm could be very special imho

Might take a little longer due to the tremendous growth in the business.

Currently @ New York Expo to spread the word in the US and attract some II's: https://www.weare121.com/121mininginvestment-new-york/cora-gold/ Don't dawdle about do they fair play to them

Oh well guess you'll have to leave us to it. I'd hardly call it a poor results though personally. If something is more effective than current treatment (much more in some cases) and safer you know what people would choose. As we can see from recent news the science does benefit people they're using drugs that are only 5% effective in people in combination therapies and it's working this company is very far from failed. And I'm certain someone will want this company bought out so it can develop/use the products in better trials or combination therapies. N6L works and Lupuzor fact.